| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 05/30/2001 | CN1297486A Anti-viral vectors |
| 05/30/2001 | CN1297481A Introduction of naked DNA or RNA encoding non-human vertebrate peptide hormones or cytokines into non-human vertebrate |
| 05/30/2001 | CN1297479A Modified adenovirus contg. fiber replacement protein |
| 05/30/2001 | CN1297478A Compositions comprising viruses and methods for concentrating virus preparations |
| 05/30/2001 | CN1297452A Modified factor VIII |
| 05/30/2001 | CN1297044A Polypeptide-human methionyl tRNA synthetase 29 and polynucleotide for coding said polypeptide |
| 05/30/2001 | CN1296975A Polypeptide-human ribosomal protein L23 and polynucleotide for coding said polypeptide |
| 05/30/2001 | CN1296967A Polypeptide-human deaf related gene 14 and polynucleotide for coding said polypeptide |
| 05/30/2001 | CN1296966A Polypeptide-human SR splicing factor 52 and polynucleotide for coding said polypeptide |
| 05/29/2001 | US6239267 Nucleotide sequence of ion channel protein associated with capsaicin; diagnosis and treatment of nervous system disorders, incontinence, stroke; antiischemic agents; antiarthritic/antiinflammatory agents; analgesics |
| 05/29/2001 | US6239265 Oligonucleotides having chiral phosphorus linkages |
| 05/29/2001 | US6239258 Human Nkx-2.2 polypeptide-encoding nucleotide sequences |
| 05/29/2001 | US6239256 Isolated muteins of proteins SCP-1, and compositions containing the mutein |
| 05/29/2001 | US6239117 Dna sequence encoding protein, expression, treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders. |
| 05/29/2001 | US6239116 Immunostimulatory nucleic acid molecules |
| 05/29/2001 | US6239106 Family of protease inhibitors, and other biologic active substances |
| 05/29/2001 | US6238921 Antisense oligonucleotide modulation of human mdm2 expression |
| 05/29/2001 | US6238918 DNA sequence encoding the tumor suppressor gene ING1 |
| 05/29/2001 | US6238915 Protein for the treament of preferential genetic disorders |
| 05/29/2001 | US6238914 Nucleic acid |
| 05/29/2001 | US6238900 Nucleotide sequence coding enzymatic polypeptide; for the prevention of bacterial infections; bactericides |
| 05/29/2001 | US6238893 Method for intracellular DNA amplification |
| 05/29/2001 | US6238887 Ribosome recycling factor (FRR) of Staphylococcus aureus |
| 05/29/2001 | US6238883 Neurotransmitter transporter SC6 |
| 05/29/2001 | US6238882 Nucleotide sequence from streptococcus; diagnosis; drug screening for new bactericides; primers; probes; antibodies; vaccines |
| 05/29/2001 | US6238881 Nucleotide sequence which codes for p115 rho-guanine exchange factor involved in cell signalling; therapeutics; diagnostics; recombinant culture production; antibodies; probes |
| 05/29/2001 | US6238859 Virus protein antigens of the JC virus |
| 05/29/2001 | US6238858 Producing secondary virus such as togavirus or retrovirus in producer host cell for subsequent infection of target cells by using chimeric primary virus or combination which direct production in the host cells; gene therapy |
| 05/29/2001 | US6238669 Proteins encoded by chicken anemia virus DNA and diagnostic kits and vaccines employing said proteins |
| 05/29/2001 | US6238666 Polypeptide |
| 05/25/2001 | WO2001036977A2 Identification of disease markers involving mass-based-separation |
| 05/25/2001 | WO2001036686A2 Genomic polymorphism for predicting therapeutic response |
| 05/25/2001 | WO2001036656A2 A complex between hyaluronic acid and a biomolecule and its use |
| 05/25/2001 | WO2001036651A1 Preparation of human or animal herpesviruses |
| 05/25/2001 | WO2001036650A2 An oncolytic adenovirus |
| 05/25/2001 | WO2001036646A1 Inhibiting gene expression with dsrna |
| 05/25/2001 | WO2001036645A2 Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same |
| 05/25/2001 | WO2001036640A2 Human fgf-21 gene and gene expression products |
| 05/25/2001 | WO2001036638A2 Polypeptides and nucleic acids encoding same |
| 05/25/2001 | WO2001036629A1 Transfer compounds, the production and the use thereof |
| 05/25/2001 | WO2001036626A2 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 05/25/2001 | WO2001036620A2 Vectors and transgenies with regulatory elements for gene delivery to the liver |
| 05/25/2001 | WO2001036618A2 Transgenic mammals into which a period 1 promoter that confers rhythmical expression has been introduced |
| 05/25/2001 | WO2001036616A2 Acid nucleic construct bearing a system regulating the expression of a gene |
| 05/25/2001 | WO2001036610A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | WO2001036605A2 2786, a human aminopeptidase |
| 05/25/2001 | WO2001036604A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 05/25/2001 | WO2001036603A2 Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
| 05/25/2001 | WO2001036602A2 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same |
| 05/25/2001 | WO2001036599A1 Microparticle-based transfection and activation of dendritic cells |
| 05/25/2001 | WO2001036589A2 Human ex vivo immune system |
| 05/25/2001 | WO2001036583A1 Continuous-flow method for preparing microparticles |
| 05/25/2001 | WO2001036487A2 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/25/2001 | WO2001036486A2 Scfv antibodies against disease associated molecules |
| 05/25/2001 | WO2001036483A1 Use of the insulin-like-growth factor i isoform mgf for the treatment of neurological disorders |
| 05/25/2001 | WO2001036476A2 Ing2, an iaps associated cell cycle protein, compositions and methods of use |
| 05/25/2001 | WO2001036470A2 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |
| 05/25/2001 | WO2001036460A2 Methods and means for regulation of gene expression |
| 05/25/2001 | WO2001036457A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/25/2001 | WO2001036456A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/25/2001 | WO2001036455A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/25/2001 | WO2001036452A2 Heteroclitic analogs of class i epitodes |
| 05/25/2001 | WO2001036446A2 Use of g-protein coupled receptors (gpcrs) and modified gpcrs for the treatment of diseases |
| 05/25/2001 | WO2001036441A1 Antisense modulation of src-3 expression |
| 05/25/2001 | WO2001036432A2 18 human secreted proteins |
| 05/25/2001 | WO2001035991A2 Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| 05/25/2001 | WO2001035935A2 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
| 05/25/2001 | WO2001035733A1 Method of acquiring immunological tolerance |
| 05/25/2001 | WO2001035732A1 An animal model for studying hormone signalling and method of modulating the signalling |
| 05/25/2001 | WO2001018039A3 INCREASED PRODUCTION OF INTERFERON-$g(a) |
| 05/25/2001 | WO2001012235A3 Targeted artificial gene delivery |
| 05/25/2001 | WO2001006005A3 Diagnostic method comprising wt1 sequences |
| 05/25/2001 | WO2000070024A3 Infectious retroviruses from a leukemic dog cell line with extensive homologies to murine leukemia viruses |
| 05/25/2001 | WO2000010588A3 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
| 05/25/2001 | WO1997013866A3 Recombinant herpes virus vectors for expression in neuronal cells |
| 05/25/2001 | CA2396428A1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/25/2001 | CA2392103A1 Human fgf-21 gene and gene expression products |
| 05/25/2001 | CA2392076A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | CA2391971A1 Methods and means for regulation of gene expression |
| 05/25/2001 | CA2391925A1 Antibodies |
| 05/25/2001 | CA2391908A1 Novel polypeptides and nucleic acids encoding same |
| 05/25/2001 | CA2391885A1 Polypeptides and nucleic acids encoding same |
| 05/25/2001 | CA2391881A1 Transfer compounds, production and use thereof |
| 05/25/2001 | CA2391622A1 Inhibiting gene expression with dsrna |
| 05/25/2001 | CA2391212A1 Methods and compositions for identifying disease markers |
| 05/25/2001 | CA2390607A1 Materials and methods for detection and treatment of breast cancer |
| 05/25/2001 | CA2390555A1 An animal model for studying hormone signalling and method of modulating the signalling |
| 05/25/2001 | CA2390548A1 Ing2, an iaps associated cell cycle protein, compositions and methods of use |
| 05/25/2001 | CA2390051A1 Thymidylate synthase polymorphism for predicting chemotherapeutic response |
| 05/25/2001 | CA2389662A1 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 05/25/2001 | CA2389613A1 Continuous-flow method for preparing microparticles |
| 05/25/2001 | CA2388777A1 18 human secreted proteins |
| 05/25/2001 | CA2386341A1 Heteroclitic analogs and related methods |
| 05/24/2001 | US20010001661 Gene delivery in various muscle cell types; gene therapy for expression of erythropoietin to treat blood disorders such as anemias, for example |
| 05/23/2001 | EP1101820A1 Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 05/23/2001 | EP1100967A2 DUPLICATIONS OF HUMAN CHROMOSOME 15q24-25 AND ANXIETY DISORDERS, DIAGNOSTIC METHODS FOR THEIR DETECTION |
| 05/23/2001 | EP1100950A1 Gastrointestinal bacterial antibody factories |
| 05/23/2001 | EP1100946A1 Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates |
| 05/23/2001 | EP1100945A2 Latency-active regulatory sequences of herpesviruses and lantency-inactive herpesviruses for gene transfer |
| 05/23/2001 | EP1100944A1 Targeted alphavirus and alphaviral vectors |